Unknown PHASE2 INTERVENTIONAL 1-arm NCT01786018

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas (TBF)

Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial

Sponsor: Azienda Ospedaliera San Giovanni Battista

Conditions B-cell Lymphoma Refractory

Interventions ATG Busulfan Collection and infusions of Donor PBSC Cyclosporine Cytoreduction Fludarabin Immunosuppression Methotrexate Thiotepa transplant (HCT)

Updated 5 times since 2017 Last updated: Jul 7, 2014 Started: Feb 28, 2013 Primary completion: Feb 28, 2015 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on B-cell Lymphoma Refractory, this trial is ongoing. The trial is conducted by Azienda Ospedaliera San Giovanni Battista and has accumulated 5 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azienda Ospedaliera San Giovanni Battista

Data source: Azienda Ospedaliera San Giovanni Battista

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Torino, Italy